CytomX Therapeutics: EpCAM Is Back, Now Prove It Holds (Rating Downgrade) [Seeking Alpha]
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: Seeking Alpha
CX-2051 shows a promising 28% response rate in late-line mCRC, but severe diarrhea remains a significant safety concern. Clarity on registrational strategy and durability of response at the 1Q26 update is crucial for CTMX's valuation and future funding. With a cash runway to 2Q27 and volatile collaboration revenue, CTMX's outlook is highly dependent on CX-2051 and CX-801 clinical progress. matdesign24/iStock via Getty Images Overview My last look at CytomX Therapeutics, Inc. ( CTMX ) was in October and followed preliminary data for its EpCAM-targeted, topo-1 Probody-ADC, CX-2051. The company is evaluating 2051 in metastatic colorectal cancer, or mCRC. Historically, ADCs have had a This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receivi
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress [Yahoo! Finance]Yahoo! Finance
- CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling [Seeking Alpha]Seeking Alpha
- What Analysts Think Is Changing the CytomX Therapeutics Story After Recent Cancer Developments [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics to Present at Upcoming December Investor Conferences [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics to Present at Upcoming December Investor ConferencesGlobeNewswire
CTMX
Earnings
- 11/6/25 - Miss
CTMX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- CTMX's page on the SEC website